Curetis AG increases Series A Financing to € 20 Million and receives ISO 13485 Certification

Addition of renowned experts to Medical Advisory Board and achievement of international quality standards generate added optimism

(lifePR) ( Holzgerlingen, )
With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through to market entry. Quality Certification for its diagnostic product development represents an additional milestone in Curetis' commercial strategy. At the same time, Curetis has added internationally recognized expertise in pneumology, intensive care medicine, and microbiology to its new Medical Advisory Board.

Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious disease testing announced a second closing for € 1.5 Million to its Series A funding. This additional financing increases the round to € 20 Million (USD 24.5 Million) and was subscribed to by one of Curetis' current investors.

Earlier this year, Curetis received ISO 13485 certification for its quality management system. The certificate demonstrates the successful implementation and use of a quality management system which conforms to the highest international quality management standard for medical devices, including IVD products. The implementation of an ISO 13485 compliant quality management system demonstrates Curetis' commitment to develop safe and effective diagnostic products. "The ISO certification reflects our strong commitment to quality and is an important milestone in the path toward regulatory clearance of our products." said Andreas Boos, Head of R&D and Managing Director.

At the same time, Curetis announced the inauguration of its new Medical Advisory Board, which will assist Curetis with the design of its clinical studies, advise on product development as well and confer with the company on future clinical applications. As initial Board members, Curetis welcomes the internationally-known microbiologist Professor Dr. Ingo Autenrieth and Professor Dr. Tobias Welte, an acknowledged expert in pneumology and intensive care medicine.

Professor Dr. Ingo Autenrieth is Medical Director of the 'Institut für Medizinische Mikrobiologie und Hygiene' of the University Clinic in Tübingen / Germany and dean of the medical faculty. Dr. Autenrieth's clinical studies focus on novel molecular diagnostic methods for diagnosis of bacterial and fungal infections. Prof. Autenrieth has been the official speaker for the 'Zentrum für Infektionsmedizin', DFG-study groups, the national 'Genomforschungsnetz' and the 'Interdisziplinäre Zentrum für Klinische Forschung Tübingen'. He serves on the supervisory board of CenTrial, as managing director at the 'Interfakultäres Institut für Mikrobiologie und Infektionsmedizin' and on the editorial board of the 'International Journal of Medical Microbiology' and of 'Infection and Immunity'.

Professor Dr. Tobias Welte leads the Division of Pneumology at the renowned Medical School in Hannover / Germany, specializing in respiratory disease and antibiotic resistance. He has been head of the 'Respiratory Intensive Care Assembly' of the European Respiratory Society and currently serves as board member of the 'Stiftung Ambulant Erworbene Pneumonie' (CAPNETZ), and the Clinical Study Center Hannover. Prof. Welte is president / fellow of various societies for intensive care medicine, in particular for pneumology and a member of multiple editorial boards in national and international journals.

"We are delighted to announce the initial appointments to our new Medical Advisory Board. The knowledge and experience of these members will help secure the continued success of Curetis", said Dr. Anne Thews, Director Marketing and Sales. "We are honored that such highly esteemed international scientific authorities have agreed to join Curetis' Advisory Board."

Curetis plans to expand this Board with additional, internationally respected experts in the future.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@lifepr.de.